Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

NCT03167619 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Olaparib Oral Product
DRUG: Olaparib Oral Product in combination with Durvalumab

Sponsor

Duke University

Collaborators

[object Object]